Title : Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.

Pub. Date : 2021 Feb

PMID : 33517269






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The growth-inhibitory effect of sorafenib was significantly enhanced by the uPA inhibitors UK122 and amiloride. Amiloride plasminogen activator, urokinase Homo sapiens